Menu Search
Equities

Starpharma Holdings Ltd

PQ6:HAM

Starpharma Holdings Ltd

Actions
  • Price (EUR)0.0545
  • Today's Change0.003 / 5.83%
  • Shares traded--
  • 1 Year change-21.01%
  • Beta--
Data delayed at least 15 minutes, as of Nov 11 2024 07:01 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.

  • Revenue in AUD (TTM)9.76m
  • Net income in AUD-8.17m
  • Incorporated1997
  • Employees50.00
  • Location
    Starpharma Holdings Ltd4-6 Southampton Crescent, AbbotsfordMELBOURNE 3067AustraliaAUS
  • Phone+61 38532-2700
  • Fax+61 39510-5955
  • Websitehttps://www.starpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.